KR102849595B1 - 안정성이 증진된 지질 기반 나노입자 - Google Patents

안정성이 증진된 지질 기반 나노입자

Info

Publication number
KR102849595B1
KR102849595B1 KR1020197028580A KR20197028580A KR102849595B1 KR 102849595 B1 KR102849595 B1 KR 102849595B1 KR 1020197028580 A KR1020197028580 A KR 1020197028580A KR 20197028580 A KR20197028580 A KR 20197028580A KR 102849595 B1 KR102849595 B1 KR 102849595B1
Authority
KR
South Korea
Prior art keywords
insulin
biotin
nanoparticles
nanoparticle
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197028580A
Other languages
English (en)
Korean (ko)
Other versions
KR20190124269A (ko
Inventor
더블유. 블레어 게호
Original Assignee
에스디지,인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스디지,인코포레이티드 filed Critical 에스디지,인코포레이티드
Publication of KR20190124269A publication Critical patent/KR20190124269A/ko
Application granted granted Critical
Publication of KR102849595B1 publication Critical patent/KR102849595B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197028580A 2017-03-13 2018-03-13 안정성이 증진된 지질 기반 나노입자 Active KR102849595B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762470478P 2017-03-13 2017-03-13
US62/470,478 2017-03-13
PCT/US2018/022182 WO2018169954A1 (en) 2017-03-13 2018-03-13 Lipid-based nanoparticles with enhanced stability

Publications (2)

Publication Number Publication Date
KR20190124269A KR20190124269A (ko) 2019-11-04
KR102849595B1 true KR102849595B1 (ko) 2025-08-22

Family

ID=63522523

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197028580A Active KR102849595B1 (ko) 2017-03-13 2018-03-13 안정성이 증진된 지질 기반 나노입자

Country Status (12)

Country Link
US (3) US20210137838A1 (enExample)
EP (1) EP3595701A4 (enExample)
JP (3) JP7306718B2 (enExample)
KR (1) KR102849595B1 (enExample)
CN (1) CN110612114A (enExample)
AU (1) AU2018236190B2 (enExample)
BR (1) BR112019018989A2 (enExample)
CA (1) CA3055561A1 (enExample)
MX (1) MX2019010852A (enExample)
SG (1) SG11201908052PA (enExample)
WO (1) WO2018169954A1 (enExample)
ZA (1) ZA201906043B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
US11077173B2 (en) 2017-03-13 2021-08-03 Sdg, Inc. Lipid-based nanoparticles and methods using same
JP7306718B2 (ja) * 2017-03-13 2023-07-11 エスディージー インコーポレイテッド 向上した安定性を有する脂質ベースのナノ粒子
AU2019205795A1 (en) * 2018-01-05 2020-07-09 Sdg, Inc. Compositions comprising lipid-based nanoparticles for treating diabetes mellitus
US20220339116A1 (en) * 2019-04-03 2022-10-27 The Johns Hopkins University Lipid nanoparticles as oral vehicles of immunotherapy
AU2020271901A1 (en) 2019-04-12 2021-11-04 Sdg, Inc. Lipid-based nanoparticles and use of same in optimized insulin dosing regimens
WO2021070778A1 (ja) * 2019-10-10 2021-04-15 株式会社カネカ ナノディスク
US20230255888A1 (en) * 2020-07-01 2023-08-17 The Research Foundation For The State University Of New York Method for preparation of liposomes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130017239A1 (en) 2010-03-24 2013-01-17 Lipotec S.A. Lipid nanoparticle capsules
US20160022711A1 (en) 2013-03-12 2016-01-28 Aribio Inc. Lipid nanomaterial containing lysophosphatidylcholine or derivative thereof and method for preparing same

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522803A (en) * 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4708861A (en) 1984-02-15 1987-11-24 The Liposome Company, Inc. Liposome-gel compositions
US4863896A (en) 1984-05-03 1989-09-05 Technology Unlimited, Inc. Diabetic control by combined insulin forms
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4762915A (en) 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
US4740375A (en) 1985-02-25 1988-04-26 Technology Unlimited, Inc. Gelcores
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
GB8522963D0 (en) 1985-09-17 1985-10-23 Biocompatibles Ltd Microcapsules
US5000960A (en) 1987-03-13 1991-03-19 Micro-Pak, Inc. Protein coupling to lipid vesicles
EP0577146A3 (en) 1988-05-16 1994-02-02 NeXstar Pharmaceuticals, Inc. Liposomes coupled to hormones
DE3919982A1 (de) 1989-06-19 1990-12-20 Liedtke Pharmed Gmbh Orale lipidarzneiform
US5104661A (en) 1989-08-14 1992-04-14 Technology Unlimited, Inc. Reverse loading of liposomes
JP2599492B2 (ja) 1990-08-21 1997-04-09 第一製薬株式会社 リポソーム製剤の製造法
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
JPH0712424B2 (ja) * 1991-06-21 1995-02-15 太陽化学株式会社 リポソーム
US5567432A (en) 1991-08-02 1996-10-22 Lau; John R. Masking of liposomes from RES recognition
US5411730A (en) 1993-07-20 1995-05-02 Research Corporation Technologies, Inc. Magnetic microparticles
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
AU3559695A (en) 1994-09-30 1996-04-26 Inex Pharmaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
GB9426484D0 (en) * 1994-12-08 1995-03-08 Ciba Geigy Ag Compositions
US6004583A (en) 1995-03-22 1999-12-21 Orex Pharmaceutical Development Corp. Protein-containing polymer composition for oral administration
US5690907A (en) 1995-06-08 1997-11-25 The Jewish Hospital Of St. Louis Avidin-biotin conjugated emulsions as a site specific binding system
US5968972A (en) 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
AU2112697A (en) 1996-02-09 1997-08-28 Pi-Wan Cheng Receptor ligand-facilitated delivery of biologically active molecules
US6207185B1 (en) 1996-03-22 2001-03-27 Bio-Sphere Technology Method for inducing a systemic immune response to an HIV antigen
US6565889B2 (en) 1996-12-02 2003-05-20 The Regents Of The University Of California Bilayer structure which encapsulates multiple containment units and uses thereof
US5795895A (en) 1997-06-13 1998-08-18 Anchors; J. Michael Combination anorexiant drug therapy for obesity using phentermine and an SSRI drug
JP2000516641A (ja) 1997-07-02 2000-12-12 エスディージー インコーポレイテッド 診断および治療用途の目標指向性リポソーム構成物
JP2001514209A (ja) 1997-09-04 2001-09-11 バイオゾーン ラボラトリーズ，インコーポレイテッド 経口リポソーム送達系
JPH11116478A (ja) 1997-10-08 1999-04-27 Taisho Pharmaceut Co Ltd 肥満防止剤
WO1999041403A1 (en) 1998-02-12 1999-08-19 The Regents Of The University Of California Compositions for receptor/liposome mediated transfection and methods of using same
US7169410B1 (en) 1998-05-19 2007-01-30 Sdg, Inc. Targeted liposomal drug delivery system
US7871641B2 (en) 1998-05-19 2011-01-18 Sdg, Inc. Hepatocyte-targeting vehicle for delivery of glargine insulin to a mammal
EP1087753A4 (en) 1998-05-19 2004-06-30 Sdg Inc TARGETED LIPOSOMAL DRUG ADMINISTRATION SYSTEM
WO1999065467A1 (en) 1998-06-16 1999-12-23 See Jackie R Method for introducing a chemical agent into the systemic circulation
EP1039880A1 (en) * 1998-10-23 2000-10-04 Idea Innovative Dermale Applikationen GmbH Method for developing, testing and using associates of macromolecules and complex aggregates for improved payload and controllable de/association rates
WO2000032167A1 (en) 1998-12-01 2000-06-08 Sdg, Inc. A polysome
US6365156B1 (en) 1999-04-16 2002-04-02 Osel, Inc. Method for improving the half-life of soluble viral-specific ligands on mucosal membranes
CA2370043A1 (en) 1999-04-23 2000-11-02 Mitsubishi Chemical Corporation Liposome bonded with antibody and polyalkylene glycol
CN1221283C (zh) 1999-05-19 2005-10-05 沈阳药科大学 口服胰岛素微粒剂及其制备方法
US7098032B2 (en) 2001-01-02 2006-08-29 Mirus Bio Corporation Compositions and methods for drug delivery using pH sensitive molecules
US6458382B1 (en) 1999-11-12 2002-10-01 Mirus Corporation Nucleic acid transfer complexes
US6761901B1 (en) 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
US20030133972A1 (en) 2000-10-11 2003-07-17 Targesome, Inc. Targeted multivalent macromolecules
AU2002232394A1 (en) 2000-10-27 2002-05-27 Wayne State University Inhibition of alpha-2 hs glycoprotein (ahsg/fetuin) in obesity and insulin control of glucose homeostasis
US7276579B2 (en) 2000-12-27 2007-10-02 Dana-Farber Cancer Institute, Inc. Immunogenic proteoliposomes, and uses thereof
US20030068361A1 (en) 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
WO2004046685A2 (en) 2002-07-15 2004-06-03 Technical Instrument San Francisco Quality control of assays
US7678386B2 (en) 2002-07-15 2010-03-16 Board Of Regents The University Of Texas Liposomes coated with selected antibodies that bind to aminophospholipids
WO2004111185A2 (en) 2002-10-30 2004-12-23 The Regents Of The University Of California Direct micro-patterning of lipid bilayers using uv light and selected uses thereof
US20050026826A1 (en) 2003-01-17 2005-02-03 Margarethe Hoenig Feline proinsulin, insulin and constituent peptides
US9872890B2 (en) 2003-03-19 2018-01-23 Paul C. Davidson Determining insulin dosing schedules and carbohydrate-to-insulin ratios in diabetic patients
WO2004097372A2 (en) 2003-04-28 2004-11-11 The Regents Of The University Of California Element-coded affinity tags
WO2004112695A2 (en) 2003-05-20 2004-12-29 Erimos Pharmaceutical Llc Methods and compositions for delivery of catecholic butanes for treatment of obesity
EP1664784A1 (en) 2003-09-17 2006-06-07 Guava Technologies, Inc. Compositions and methods for analysis of target analytes
US20050175541A1 (en) 2003-11-19 2005-08-11 Lanza Gregory M. Enhanced drug delivery
US20050202075A1 (en) 2004-03-12 2005-09-15 Pardridge William M. Delivery of genes encoding short hairpin RNA using receptor-specific nanocontainers
US7511016B2 (en) 2004-07-07 2009-03-31 Mosamedix B.V. Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
AU2006249480A1 (en) 2005-05-23 2006-11-30 Sdg, Inc. Lipid construct for delivery of insulin to a mammal
US20070218117A1 (en) * 2006-03-20 2007-09-20 Sdg, Inc. Supra molecular construct for delivery of interferon to a mammal
US20110135725A1 (en) 2005-05-23 2011-06-09 Sdg, Inc. Lipid Construct for Delivery of Insulin to a Mammal
ZA200710056B (en) * 2005-05-23 2009-03-25 Sdg Inc Lipid construct for delivery of interferon to a mammal
CN101217965B (zh) 2005-07-07 2012-07-18 学校法人浦项工科大学校 葡萄糖吸收调节剂和用于治疗糖尿病或糖尿病并发症的方法
CN1895224A (zh) 2006-06-26 2007-01-17 裴泽军 多烯磷脂酰胆碱脂质体制剂及其制备方法
US9814672B2 (en) 2007-03-09 2017-11-14 Susan T. Laing Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi
US20100080773A1 (en) 2008-09-26 2010-04-01 Sdg, Inc. Orally Bioavailable Lipid-Based Constructs
US9145453B2 (en) 2007-09-28 2015-09-29 Sdg, Inc. Orally bioavailable lipid-based constructs
US8962015B2 (en) * 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
US8846053B2 (en) 2008-09-26 2014-09-30 Sdg, Inc. Orally bioavailable lipid-based constructs
EP2285361A2 (en) * 2008-05-01 2011-02-23 Nod Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of making and using same
US20120035105A1 (en) 2009-01-09 2012-02-09 Sdg, Inc. Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments
GB2477545B (en) * 2010-02-05 2011-12-21 Special Products Ltd A liquid morphine composition for buccal administration
GB201215289D0 (en) * 2012-08-28 2012-10-10 Medical Res Council Nanoparticle formulation
EP3247363A4 (en) * 2015-01-21 2018-10-03 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
US20170319573A1 (en) * 2015-10-16 2017-11-09 Ipsen Biopharm Ltd. Stabilizing Camptothecin Pharmaceutical Compositions
US20180110771A1 (en) 2016-10-21 2018-04-26 Ipsen Biopharm Ltd. Liposomal Irinotecan Preparations
JP7306718B2 (ja) * 2017-03-13 2023-07-11 エスディージー インコーポレイテッド 向上した安定性を有する脂質ベースのナノ粒子
US11077173B2 (en) * 2017-03-13 2021-08-03 Sdg, Inc. Lipid-based nanoparticles and methods using same
AU2019205795A1 (en) 2018-01-05 2020-07-09 Sdg, Inc. Compositions comprising lipid-based nanoparticles for treating diabetes mellitus
AU2020271901A1 (en) * 2019-04-12 2021-11-04 Sdg, Inc. Lipid-based nanoparticles and use of same in optimized insulin dosing regimens

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130017239A1 (en) 2010-03-24 2013-01-17 Lipotec S.A. Lipid nanoparticle capsules
US20160022711A1 (en) 2013-03-12 2016-01-28 Aribio Inc. Lipid nanomaterial containing lysophosphatidylcholine or derivative thereof and method for preparing same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
V.V. Kumar et al. Biophysical Journal. 1989, vol.55, pp.789-792*
V.V. Kumar et al. Lysophosphatidylcholine stabilizes small unilamellar phosphatidylcholine vesicles. Biophysical Journal. 1989, vol.55, pp.789-792*
대한민국 공개특허공보 제10-2008-0043742호(2008.05.19.) 1부.*

Also Published As

Publication number Publication date
JP7656353B2 (ja) 2025-04-03
US20210137838A1 (en) 2021-05-13
CA3055561A1 (en) 2018-09-20
US20230172868A1 (en) 2023-06-08
AU2018236190A1 (en) 2019-09-26
KR20190124269A (ko) 2019-11-04
ZA201906043B (en) 2022-11-30
US11071715B2 (en) 2021-07-27
JP7306718B2 (ja) 2023-07-11
BR112019018989A2 (pt) 2020-04-14
US20200022922A1 (en) 2020-01-23
EP3595701A4 (en) 2021-01-06
CN110612114A (zh) 2019-12-24
EP3595701A1 (en) 2020-01-22
JP2020510705A (ja) 2020-04-09
JP2025085727A (ja) 2025-06-05
MX2019010852A (es) 2019-10-30
SG11201908052PA (en) 2019-09-27
JP2023120371A (ja) 2023-08-29
AU2018236190B2 (en) 2025-02-20
WO2018169954A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
KR102849595B1 (ko) 안정성이 증진된 지질 기반 나노입자
US20250288521A1 (en) Orally bioavailable lipid-based constructs
AU2024266969A1 (en) Compositions comprising lipid-based nanoparticles for treating diabetes mellitus
US11077173B2 (en) Lipid-based nanoparticles and methods using same
US20240139288A1 (en) Lipid-based nanoparticles and use of same in optimized insulin dosing regimens
HK40015408A (en) Lipid-based nanoparticles with enhanced stability

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601